Attralus touts amyloid imaging research at SNMMI 2021

Biopharmaceutical company Attralus is directing attention to research presented this week at the annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) involving its AT-01 amyloid imaging agent.

In an oral presentation and posters, clinical data showed that AT-01 -- a radiolabeled, synthetic amyloid-targeted peptide designed for imaging of systemic amyloid deposits -- enabled detection of seven types of amyloid on PET/CT exams, according to Attralus. It also identified amyloid in anatomic sites not detected clinically, including presymptomatic cardiac amyloid, the company said.

AT-01 is currently being evaluated in a Phase 1/2 clinical trial in patients with a range of types of systemic amyloidosis, according to Attralus.